Please assess the completion status of the following clinical trial:

Trial Title: The LANCET Trial: A Trial of Long-acting Insulin Injection to Reduce C-reactive Protein in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women aged 18 to 79~* Type 2 diabetes, treated only by diet or oral drugs other than metformin~* HbA1c greater than or equal to 7% and less than or equal to 10%~* C-reactive protein greater than or equal to 2 mg/L~Exclusion Criteria:~* Baseline use of metformin or insulin~* Type 1 diabetes, history of ketoacidosis or positive anti-GAD antibody~* History of congestive heart failure requiring drug therapy~* Active liver disease~* Kidney impairment~* Recent initiation or change in dose of statins, fibric acid derivatives, angiotensin receptor blockers, nonsteroidal anti-inflammatory agents, or corticosteroids

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Placebo pill (Type: PLACEBO_COMPARATOR): Placebo pill
- Metformin Pill (Type: ACTIVE_COMPARATOR): Metformin pill
- Insulin Glargine plus placebo pill (Type: ACTIVE_COMPARATOR): Insulin glargine plus placebo pill
- Insulin Glargine plus metformin pill (Type: ACTIVE_COMPARATOR): Insulin Glargine plus metformin pill

Based on this trial design, predict the completion outcome and termination type (if applicable).